Even though AD is a public health issue, as of now, there is only two classes of drugs approved to treat AD, including inhibitors to cholinesterase enzyme (naturally derived, synthetic and hybrid analogs) and antagonists to N-methyl d-aspartate (NMDA) (Breijyeh and Karaman 2020; Thoe et al. 2021). The gene discussed is BCHE; the disease is Alzheimer disease.